Antibacterial fatty acids: An update of possible mechanisms of action and implications in the development of the next-generation of antibacterial agents

Abstract

The antibacterial activity of fatty acids (FA) is well known in the literature and represents a promising option for developing the next-generation of antibacterial agents to treat a broad spectrum of bacterial infections. FA are highly involved in living organisms' defense system against numerous pathogens, including multidrug-resistant bacteria. When combined with other antibacterial agents, the remarkable ability of FA to enhance their bactericidal properties is a critical feature that is not commonly observed in other naturally-occurring compounds. More reviews focusing on FA antibacterial activity, traditional and non-traditional mechanisms and biomedical applications are needed. This review is intended to update the reader on the antibacterial properties of recent FA and how their chemical structures influence their antibacterial activity. This review also aims to better understand both traditional and non-traditional mechanisms involved in these recently explored FA antibacterial activities.

References 73

1. 1.

   Desbois A, Smith V. Antibacterial free fatty acids: Activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol 2010;85(6):1629–42.

   Not in our library10.1007/s00253-009-2355-3

2. 2.

   Kabara J, Swieczkowski D, Conley A, Truant J. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother 1972;2(1):23–8.

   Not in our library10.1128/aac.2.1.23

3. 3.

   Venkata Mohan S, Rohit M, Chiranjeevi P, Chandra R, Navaneeth B. Heterotrophic microalgae cultivation to synergize biodiesel production with waste remediation: Progress and perspectives. Bioresour Technol 2015;184:169–78.

   Not in our library10.1016/j.biortech.2014.10.056

4. 4.

   Desbois A Potential applications of antimicrobial fatty acids in medicine, agriculture and other industries. Recent Pat Antiinfect Drug Discov 2012;7(2):111–22.

   Not in our library10.2174/157489112801619728

5. 5.

   Centers for Disease Control and Prevention (CDC). Antibiotic/Antimicrobial Resistance. https://www.cdc.gov/drugresistance/;.. 2020. accessed 21 January 2021.

   Not in our library

6. 6.

   Yin H, Li G, Chen X, Wang W, Wong P, Zhao H, Accelerated evolution of bacterial antibiotic resistance through early emerged stress responses driven by photocatalytic oxidation. Appl Catal B 2020;269:118829.

   Not in our library

7. 7.
   Antibacterial Free Fatty Acids and Monoglycerides: Biological Activities, Experimental Testing, and Therapeutic Applications · 2018

   No notice
8. 8.

   Kumar P, Lee J, Beyenal H, Lee J. Fatty acids as antibiofilm and antivirulence agents. Trends Microbiol 2020;28(9):753–68.

   Not in our library10.1016/j.tim.2020.03.014

9. 9.

   Sanabria-Ríos D, Morales-Guzmán C, Mooney J, Medina S, Pereles-De–León T, Rivera-Román A, Antibacterial activity of hexadecynoic acid isomers toward clinical isolates of multidrug-resistant Staphylococcus aureus. Lipids 2020;55(2): 101–16.

   Not in our library10.1002/lipd.12213

10. 10.

    Pushparaj Selvadoss P, Nellore J, Balaraman Ravindrran M, Sekar U, Tippabathani J. Enhancement of antimicrobial activity by liposomal oleic acid-loaded antibiotics for the treatment of multidrug-resistant Pseudomonas aeruginosa. Artif Cells Nanomed Biotechnol 2018;46(2):268–73.

    Not in our library10.1080/21691401.2017.1307209

11. 11.

    Nakatsuji T, Kao MC, Fang JY, Zouboulis CC, Zhang L, Gallo RL, Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol 2009;129 (10):2480–8.

    Not in our library10.1038/jid.2009.93

12. 12.

    Yang H, Chen J, Rathod J, Jiang Y, Tsai P, Hung Y, Lauric acid is an inhibitor of Clostridium difficile growth in vitro and reduces inflammation in a mouse infection model. Front Microbiol 2017;8:2635.

    Not in our library10.3389/fmicb.2017.02635

13. 13.
    Fatty acid extracts from <it>Lucilia sericata </it>larvae promote murine cutaneous wound healing by angiogenic activity · 2010

    Not checked
14. 14.

    Huang W, Tsai T, Chuang L, Li YY, Zouboulis C, Tsai P. Anti-bacterial and anti-inflammatory properties of capric acid against Propionibacterium acnes: A comparative study with lauric acid. J Dermatol Sci 2014;73(3):232–40.

    Not in our library10.1016/j.jdermsci.2013.10.010

15. 15.

    Ivanova E, Nguyen S, Guo Y, Baulin V, Webb H, Truong V, Bactericidal activity of self-assembled palmitic and stearic fatty acid crystals on highly ordered pyrolytic graphite. Acta Biomater 2017;59:148–57.

    Not in our library10.1016/j.actbio.2017.07.004

16. 16.

    Nitbani F, Jumina J, Siswanta D, Sholikhah E. Isolation and antibacterial activity test of lauric acid from crude coconut oil (Cocos nucifera L.). Procedia Chem 2016; 18:132–40.

    Not in our library

17. 17.

    Abel-Anzaku A, Akyala J, Adeola J, Ewenighi C. Antibacterial activity of lauric acid on some selected clinical isolates. Ann Clin Lab Res 2017;05:1–5.

    Not in our library

18. 18.

    Nagase S, Matsue M, Mori Y, Honda-Ogawa M, Sugitani K, Sumitomo T, Comparison of the antimicrobial spectrum and mechanisms of organic virgin coconut oil and lauric acid against bacteria. J Wellness Health Care 2017;41(1): 87–95.

    Not in our library

19. 19.

    Yoon B, Jackman J, Kim M, Cho N. Spectrum of membrane morphological responses to antibacterial fatty acids and related surfactants. Langmuir 2015;31 (37):10223–32.

    Not in our library10.1021/acs.langmuir.5b02088

20. 20.

    Kim S, Rhee M. Highly enhanced bactericidal effects of medium chain fatty acids (caprylic, capric, and lauric acid) combined with edible plant essential oils (carvacrol, eugenol, β-resorcylic acid, trans-cinnamaldehyde, thymol, and vanillin) against Escherichia coli O157:H7. Food Control 2016;60:447–54.

    Not in our library

21. 21.

    Cheung Lam A, Sandoval N, Wadhwa R, Gilkes J, Do T, Ernst W, Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic. BMC Res Notes 2016;9:337.

    Not in our library10.1186/s13104-016-2138-8

22. 22.

    Carballeira N, Montano N, Morales C, Mooney J, Torres X, Díaz D, 2-Methoxylated FA display unusual antibacterial activity towards clinical isolates of Methicillin-resistant Staphylococcus aureus (CIMRSA) and Escherichia coli. Lipids 2017;52(6):535–48.

    Not in our library10.1007/s11745-017-4262-1

23. 23.

    Sanabria-Ríos D, Rivera-Torres Y, Rosario J, Gutierrez R, Torres-García Y, Montano N, Chemical conjugation of 2-hexadecynoic acid to C5-curcumin enhances its antibacterial activity against multi-drug resistant bacteria. Bioorg Med Chem Lett 2015;25(22):5067–71.

    Not in our library10.1016/j.bmcl.2015.10.022

24. 24.
    Prevention of Ophthalmia Neonatorum Caused by <italic toggle="yes">Neisseria gonorrhoeae</italic> Using a Fatty Acid-Based Formulation · 2017

    Not checked
25. 25.

    Fares N, Abu-Harirah H. The sensitivity and specificity of available Helicobacter pylori diagnosis techniques considering the emerging multidrug resistance. Drug Invention Today 2020;12(11):2736–40.

    Not in our library

26. 26.

    Sun M, Zhou Z, Dong J, Zhang J, Xia Y, Shu R. Antibacterial and antibiofilm activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against periodontopathic bacteria. Microb Pathog 2016;99:196–203.

    Not in our library10.1016/j.micpath.2016.08.025

27. 27.

    Sun M, Dong J, Xia Y, Shu R. Antibacterial activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against planktonic and biofilm growing Streptococcus mutans. Microb Pathog 2017;107:212–8.

    Not in our library10.1016/j.micpath.2017.03.040

28. 28.

    Le P, Desbois A. Antibacterial effect of eicosapentaenoic acid against Bacillus cereus and Staphylococcus aureus: Killing kinetics, selection for resistance, and potential cellular target. Mar Drugs 2017;15(11):334.

    Not in our library10.3390/md15110334

29. 29.

    Butt U, ElShaer A, Snyder L, Chaidemenou A, Alany R. Fatty acid microemulsion for the treatment of neonatal conjunctivitis: Quantification, characterisation and evaluation of antimicrobial activity. Drug Deliv Transl Res 2016;6(6):722–34.

    Not in our library10.1007/s13346-016-0338-3

30. 30.
    Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori. · 2015

    Not checked
31. 31.

    Seabra C, Nunes C, Gomez-Lazaro M, Correia M, Machado J, Gonçalves I, Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. Int J Pharm 2017;519(1–2):128–37.

    Not in our library10.1016/j.ijpharm.2017.01.014

32. 32.

    Habbu P, Warad V, Shastri R, Madagundi S, Kulkarni V. Antimicrobial metabolites from marine microorganisms. Chin J Nat Med 2016;14(2):101–16.

    Not in our library10.1016/s1875-5364(16)60003-1

33. 33.

    Kwan J, Meickle T, Ladwa D, Teplitski M, Paul V, Luesch H. Lyngbyoic acid, a “tagged” fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa. Mol Biosyst 2011;7(4):1205–16.

    Not in our library10.1039/c0mb00180e

34. 34.

    Amiri Moghaddam J, Dávila-Céspedes A, Kehraus S, Crüsemann M, Köse M, Müller C, Cyclopropane-containing fatty acids from the marine bacterium Labrenzia sp. 011 with antimicrobial and GPR84 activity. Mar Drugs 2018;16(10): 369.

    Not in our library10.3390/md16100369

35. 35.

    Dasagrandhi C, Ellamar J, Kim Y, Kim H. Antimicrobial activity of a novel furan fatty acid, 7,10-epoxyoctadeca-7,9-dienoic acid against methicillin-resistant Staphylococcus aureus. Food Sci Biotechnol 2016;25(6):1671–5.

    Not in our library10.1007/s10068-016-0257-6

36. 36.

    Dasagrandhi C, Kim Y, Kim I, Hou C, Kim H. 7,10-Epoxyoctadeca-7,9-dienoic acid: A small molecule adjuvant that potentiates β-lactam antibiotics against multidrug-resistant Staphylococcus aureus. Indian J Microbiol 2017;57(4):461–9.

    Not in our library10.1007/s12088-017-0680-2

37. 37.

    Sanabria-Ríos D, Rivera-Torres Y, Maldonado-Domínguez G, Domínguez I, Ríos C, Díaz D, Antibacterial activity of 2-alkynoic fatty acids against multidrug-resistant bacteria. Chem Phys Lipids 2014;178:84–91.

    Not in our library10.1016/j.chemphyslip.2013.12.006

38. 38.

    Liu C, Li X, Cheng R, Han Z, Yang L, Song Z, Anti-oral common pathogenic bacterial active acetylenic acids from Thesium chinense Turcz. J Nat Med 2018;72 (2):433–8.

    Not in our library10.1007/s11418-018-1180-3

39. 39.

    Carballeira N New advances in the chemistry of methoxylated lipids. Prog Lipid Res 2002;41(6):437–56.

    Not in our library10.1016/s0163-7827(02)00005-x

40. 40.

    van Eijk E, Wittekoek B, Kuijper E, Smits W. DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. J Antimicrob Chemother 2017;72(5):1275–84.

    Not in our library10.1093/jac/dkw548

41. 41.

    Koch A Bacterial wall as target for attack: Past, present, and future research. Clin Microbiol Rev 2003;16(4):673–87.

    Not in our library10.1128/cmr.16.4.673-687.2003

42. 42.

    Arenz S, Wilson D. Bacterial protein synthesis as a target for antibiotic inhibition. Cold Spring Harb Perspect Med 2016;6(9):a025361.

    Not in our library10.1101/cshperspect.a025361

43. 43.

    Epand R, Walker C, Epand R, Magarvey N. Molecular mechanisms of membrane targeting antibiotics. Biochim Biophys Acta 2016;1858(5):980–7.

    Not in our library10.1016/j.bbamem.2015.10.018

44. 44.

    Murima P, McKinney J, Pethe K. Targeting bacterial central metabolism for drug development. Chem Biol 2014;21(11):1423–32.

    Not in our library10.1016/j.chembiol.2014.08.020

45. 45.

    Tomašič T, Katsamakas S, Hodnik Ž, Ilaš J, Brvar M, Solmajer T, Discovery of 4,5,6,7-tetrahydrobenzo[1,2-d] thiazoles as novel DNA gyrase inhibitors targeting the ATP-binding site. J Med Chem 2015;58(14):5501–21.

    Not in our library10.1021/acs.jmedchem.5b00489

46. 46.

    Scheffers D, Pinho M. Bacterial cell wall synthesis: New insights from localization studies. Microbiol Mol Biol Rev 2005;69(4):585–607.

    Not in our library10.1128/mmbr.69.4.585-607.2005

47. 47.

    Vollmer W, Blanot D, de Pedro M. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008;32(2):149–67.

    Not in our library10.1111/j.1574-6976.2007.00094.x

48. 48.

    Schumann P Peptidoglycan Structure. In: Rainey F, Oren A, editors. Methods in Microbiology. London: Academic Press; 2011, p. 101–29.

    Not in our library

49. 49.
    The Staphylococcus aureus Response to Unsaturated Long Chain Free Fatty Acids: Survival Mechanisms and Virulence Implications · 2009

    No notice
50. 50.

    Zheng C, Yoo J, Lee T, Cho H, Kim Y, Kim W. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett 2005;579(23):5157–62.

    Not in our library10.1016/j.febslet.2005.08.028

51. 51.

    Plecha S, Withey J. Mechanism for inhibition of Vibrio cholerae ToxT activity by the unsaturated fatty acid components of bile. J Bacteriol 2015;197(10):1716–25.

    Not in our library10.1128/jb.02409-14

52. 52.

    Withey J, Nag D, Plecha S, Sinha R, Koley H. Conjugated Linoleic Acid Reduces Cholera Toxin Production In Vitro and In Vivo by Inhibiting Vibrio cholerae ToxT Activity. Antimicrob Agents Chemother 2015;59(12):7471–6.

    Not in our library10.1128/aac.01029-15

53. 53.

    Cartron M, England S, Chiriac A, Josten M, Turner R, Rauter Y, Bactericidal activity of the human skin fatty acid cis-6-hexadecanoic acid on Staphylococcus aureus. Antimicrob Agents Chemother 2014;58(7):3599–609.

    Not in our library10.1128/aac.01043-13

54. 54.

    Parsons J, Frank M, Subramanian C, Saenkham P, Rock C. Metabolic basis for the differential susceptibility of gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci U S A 2011;108(37):15378–83.

    Not in our library10.1073/pnas.1109208108

55. 55.

    Parsons J, Yao J, Frank M, Jackson P, Rock C. Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. J Bacteriol 2012;194(19):5294–304.

    Not in our library10.1128/jb.00743-12

56. 56.

    Baquero F, Coque T, De la Cruz F. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother 2011;55(8):3649–60.

    Not in our library10.1128/aac.00013-11

57. 57.

    Getino M, Sanabria-Ríos D, Fernández-López R, Campos-Gómez J, Sánchez-López J, Fernández A, Synthetic fatty acids prevent plasmid-mediated horizontal gene transfer. mBio 2015;6(5). e01032–01015.

    Not in our library10.1128/mbio.01032-15

58. 58.

    Ripoll-Rozada J, García-Cazorla Y, Getino M, Machón C, Sanabria-Ríos D, de la Cruz F, Type IV traffic ATPase TrwD as molecular target to inhibit bacterial conjugation. Mol Microbiol 2016;100(5):912–21.

    Not in our library10.1111/mmi.13359

59. 59.

    Christie P, Whitaker N, González-Rivera C. Mechanism and structure of the bacterial type IV secretion systems. Biochim Biophys Acta 2014;1843(8):1578–91.

    Not in our library10.1016/j.bbamcr.2013.12.019

60. 60.

    De la Cruz F, Davies J. Horizontal gene transfer and the origin of species: Lessons from bacteria. Trends Microbiol 2000;8(3):128–33.

    Not in our library10.1016/s0966-842x(00)01703-0

61. 61.

    García-Cazorla Y, Getino M, Sanabria-Ríos D, Carballeira N, de la Cruz F, Arechaga I, Conjugation inhibitors compete with palmitic acid for binding to the conjugative traffic ATPase TrwD, providing a mechanism to inhibit bacterial conjugation. J Biol Chem 2018;293(43):16923–30.

    Not in our library10.1074/jbc.ra118.004716

62. 62.

    Brackman G, Cos P, Maes L, Nelis H, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother 2011;55(6):2655–61.

    Not in our library10.1128/aac.00045-11

63. 63.

    Ng W, Bassler B. Bacterial quorum-sensing network architectures. Annu Rev Genet 2009;43:197–222.

    Not in our library10.1146/annurev-genet-102108-134304

64. 64.

    Cui C, Song S, Yang C, Sun X, Huang Y, Li K, Disruption of quorum sensing and virulence in Burkholderia cenocepacia by a structural analogue of the cis-2-dodecenoic acid signal. Appl Environ Microbiol 2019;85(8):e00105–19.

    Not in our library10.1128/aem.00105-19

65. 65.

    Wagner V, Frelinger J, Barth R, Iglewski B. Quorum sensing: Dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol 2006;14(2):55–58.

    Not in our library10.1016/j.tim.2005.12.002

66. 66.
    Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective · 2018

    No notice
67. 67.

    Nicol M, Alexandre S, Luizet J, Skogman M, Jouenne T, Salcedo S, Unsaturated fatty acids affect quorum sensing communication system and inhibit motility and biofilm formation of Acinetobacter baumannii. Int J Mol Sci 2018;19 (1):214.

    Not in our library10.3390/ijms19010214

68. 68.

    Miller M, Bassler B. Quorum sensing in bacteria. Annu Rev Microbiol 2001;55: 165–99.

    Not in our library10.1146/annurev.micro.55.1.165

69. 69.

    Widmer K, Soni K, Hume M, Beier R, Jesudhasan P, Pillai S. Identification of poultry meat-derived fatty acids functioning as quorum sensing signal inhibitors to autoinducer-2 (AI-2). J Food Sci 2007;72(9):M363–8.

    Not in our library10.1111/j.1750-3841.2007.00527.x

70. 70.

    Kiratisin P, Tucker KD, Passador L. LasR, a transcriptional activator of Pseudomonas aeruginosa virulence genes, functions as a multimer. J Bacteriol 2002;184(17): 4912–9.

    Not in our library10.1128/jb.184.17.4912-4919.2002

71. 71.
    Multidrug Efflux Pumps in Staphylococcus aureus: an Update · 2013

    No notice
72. 72.

    Poole K Bacterial multidrug efflux pumps serve other functions. Microbe 2008;3 (4):179–85.

    Not in our library

73. 73.

    Tintino S, Oliveira-Tintino C, Campina F, Silva R, Costa Mdo S, Menezes I, Evaluation of the tannic acid inhibitory effect against the NorA efflux pump of Staphylococcus aureus. Microb Pathog 2016;97:9–13.

    Not in our library10.1016/j.micpath.2016.04.003

Cited by papers we hold 1

• Review of Eukaryote Cellular Membrane Lipid Composition, with Special Attention to the Fatty Acids · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.